Placeholder

Cyclophosphamide

  • # LGM Pharma is a Cyclophosphamide CAS# 50-18-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Cyclophosphamide
  • CAS #: 50-18-0
  • Mode of Action:

    Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

  • Pharmacodynamics:

    Cyclophosphamide is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.

  • Metabolism:

    Metabolism and activation occurs at the liver. 75% of the drug is activated by cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The CYP2B6 isoform is the enzyme with the highest 4-hydroxylase activity. Cyclophosphamide undergoes activation to eventually form active metabolites, phosphoramide mustard and acrolein. Cyclophosphamide appears to induce its own metabolism which results in an overall increase in clearance, increased formation of 4-hydroxyl metabolites, and shortened t1/2 values following repeated administration.

  • Toxicity:

    Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea.

  • IUPAC: N, N-bis(2-chloroethyl)-1, 3, 2-oxazaphosphinan-2-amine 2-oxide
  • ATC: L01AA01
  • PubChem: 2907
  • DrugBank: APRD00408
  • Formula: C7 H15 N2 O2
  • Molecular Mass: 261.086
  • Synonyms: (+-)-Cyclophosphamide, (RS)-Cyclophosphamide, 1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin, 2-(Bis(2-chloroethyl)amino)-2H-1,3,2-oxazaphosphorine 2-oxide, 2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazophosphorine 2-oxide, 4-27-00-09750 (Beilstein Handbook Reference), 4-Hydroxy-cyclophosphan-mamophosphatide, AI3-26198, ASTA B518, B 518, Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester, BRN 0011744, CB 4564, CCRIS 188, Ciclofosfamida, Ciclofosfamida [INN-Spanish], Ciclophosphamide, Ciclophosphamide [INN], Clafen, Claphene, Cyclophosphamid, Cyclophosphamide, Cyclophosphamidum, Cyclophosphamidum [INN-Latin], Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclophosphoramide, Cyclostin, Cyklofosfamid, Cyklofosfamid [Czech], Cytophosphan, Cytophosphane, Cytoxan, D,L-Cyclophosphamide, EINECS 200-015-4, Endoxan, Endoxan R, Endoxan-asta, Endoxana, Endoxanal, Genoxal, HSDB 3047, Lyophilized cytoxan, N,N-Bis(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide, N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide, N,N-Bis(beta-chloroethyl)-N',O-propylenephosphoric acid ester diamide, N,N-Bis(beta-chloroethyl)-N',O-trimethylenephosphoric acid ester diamide, N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid, N,N-Bis-(beta-chloraethyl)-N',O-propylen-phosphorsaeure-ester-diamid [German], N,N-Di(2-chloroethyl)-N,O-propylene-phosphoric acid ester diamide, NCI-C04900, Neosar, NSC 26271, NSC-26271, Occupation, cyclophosphamide exposure, Phosphorodiamidic acid, N,N-bis(2-chloroethyl)-N'-(3-hydroxypropyl)-, intramol. ester, Procytox, RCRA waste number U058, Sendoxan, SK 20501, UNII-6UXW23996M, Zyklophosphamid, Zyklophosphamid [German]
  • SMILES: N([P@@]1(NCCCO1)=O)(CCCl)CCCl
  • AHFS Code: 10:00.0
  • InChl: 1S/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)
  • General Reference:
    1. Brock N: The history of the oxazaphosphorine cytostatics. Cancer. 1996 Aug 1;78(3):542-7. Pubmed
    2. Brock N: Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res. 1989 Jan 1;49(1):1-7. Pubmed
    3. FDA label
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service